Best of ASCO - 2014 Annual Meeting

 

Welcome

Tissue-Based Biomarkers

Developmental Therapeutics and Tumor Biology (Nonimmuno)

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A large subtype of squamous cell carcinoma enriched for TrkB-T1 mRNA.

Yalu Zhou

e14751

A prognostic 10-miRNA risk score (10-miRNA RS) in predicting neoadjuvant chemotherapy sensitivity of luminal breast cancer.

Chang Gong

3139

Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.

Arielle Lutterman Heeke

3132

ALK actionable mutations (muts) within cancer types and their responses to crizotinib (CZ).

Lin Li

e14739

ALK resistance mutations (muts) developed in different ALK fusion types.

Jun Zhao

e14741

An aggressive RhoC phenotype is associated with relapse after external beam radiation therapy of a prostate cancer xenograft model.

Oskar Vilhelmsson Timmermand

e14748

Analysis of lipid metabolism genes in advanced small cell lung cancer.

Maria Merino

e14737

Association of Ras-Raf-MEK-Erk/JNK pathway mutations with overall survival for lung squamous cell carcinoma patients.

Long Xu

e14754

BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials.

Madiha Naseem

3145

CD205, a target antigen for a novel ADC: Evaluation of antigen expression on TNBC, pancreatic adenocarcinoma and bladder urothelial carcinoma.

Simona Massa

e14726

Changes in TROP2 expression in lung cancer patients receiving anticancer treatments.

Shota Omori

e14732

Clinicopathologic characteristics of NRG1 fusion-positive cancers: A single-institution study.

Alison M. Schram

3129

Cytoplasmic cyclin E independently predicts recurrence in older patients with primary breast cancer.

Simon Johnston

3128

Differential copy number alteration profiles among gynecological malignancies.

Ignacio Romero

e14744

Effects of immune architecture on response to adjuvant capecitabine in triple-negative breast cancer (FinXX trial).

Saranya Chumsri

3142

HER family protein expression and activation predicts response to combination T-DM1/pertuzumab in HER2+ patients in the I-SPY 2 TRIAL.

Julia Dianne Wulfkuhle

3133

HER2 targeted therapy and outcome in HER2-equivocal cases after 2018 ASCO/CAP HER2 guideline modification.

James Crespo

e14729

IDH1 polymorphism G105G (rs11554137) as a prognostic factor in gliomas.

Enrico Franceschi

e14734

Leeomic: A comprehensive proteomic analysis towards discovery of predictive patterns of protein expression to ribociclib sensitivity and resistance—A compLEEment-1 Canadian correlative sub-study.

Stephen K. L. Chia

TPS3170

Machine learning methods with salivary metabolomics for breast cancer detection.

Takeshi Murata

3135

Measuring phospho-MET by multiplex immunofluorescence to aid in selection of patients with MET activation in tumors.

Tony Navas

3131

MET exon 14 skipping analogs: Rare but potentially clinically actionable.

Rebecca Feldman

3141

Molecular differences between lymph nodes (LNs) and distant metastases (mets) in colorectal cancer (CRC).

Alberto Puccini

3130

Morphologic and genomic characterization of circulating tumor cells in patients with metastatic colorectal cancer treated with combinational treatment of andecaliximab, bevacizumab and chemotherapy.

Stephanie Shishido

e14753

Multiplatform molecular profiling: Observational study to determine the effect of treatment selection in advanced or refractory metastatic solid tumors.

Faraz A. Khan

e14730

Multiplex genomic testing (MGT): Four-year real-world experience of two community oncology practices in central rural Nebraska.

Mehmet Sitki Copur

e14728

Mutation and treatment profiles of patients with concurrent EGFR and ALK actionable mutations (muts).

Jun Zhao

3138

p53 expression and clinical outcomes in untreated and treated breast cancer patients after long-term follow-up.

Sherry X. Yang

e14745

Pharmacodynamics of PI3K, MEK, and AKT inhibitors through isoform-specific measurements of MEK, ERK, AKT, and ribosomal protein S6 in needle biopsies.

William Herrick

3134

Prediction of biomarker status, diagnosis and outcome from histology slides using deep learning-based hypothesis free feature extraction.

Eldad Klaiman

3140

Prospective observational study for treatment resistance-related gene screening using plasma circulating tumor DNA in the third generation EGFR TKI osimertinib therapy elucidator.

Akihiro Tamiya

TPS3171

Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability.

Aurelie Moreira

e14750

Reassignment of HER2 status for subgroups of breast cancer according to the 2018 updated American Society of Clinical Oncology and College of American Pathologists guidelines: The impact of combined immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) reflex testing in a large national reference laboratory.

Katherine Geiersbach

3144

Receptor status conversion between primary and recurrent/metastatic breast cancer: A single institutional study.

Poornima Ramadas

e14735

Somatic mutations in non-small cell lung cancer and their correlation with overall survival, tumor mutation burden, and programmed-death cell ligand-1 (PD-L1) status.

Jennifer Dotson

e14752

Targeted-sequencing in rare cancers and the impact on patient treatment.

Hitomi Sumiyoshi Okuma

e14755

The Cancer Molecular Screening and Therapeutics Program (MoST): Actionable mutation frequencies in a population with rare and less common cancers.

Subotheni Thavaneswaran

3136

The impact of androgen receptor (AR) expression on the prognosis of ductal carcinoma in situ (DCIS).

Choong Man Lee

e14731

The prognostic role of a novel TP53 mutation classifier in resectable esophageal squamous-cell carcinoma.

Dan Su

e14749

The whole genome landscape of adult metastatic sarcoma.

Eric Yang Zhao

3137

Therapy alteration of solid tumors based on FoundationOne comprehensive genome profiling assay.

Kirill Karlin

e14742

Tumor mutational burden reference materials for assay standardization.

Matt Butler

e14746

Urinary excretion of components of the renin-angiotensin-aldosterone system in patients having localized renal cancer.

Roman Osokin

e14725

Utility of the Breast Cancer Index (BCI) in the clinical practice.

Saranya Kodali

e14723

Vascular endothelial growth factor A (VEGF-A) amplification and long-term response to ramucirumab (ram) in metastatic gastric cancer (mGC): The VERA study.

Alessandra Raimondi

3143